First Wave BioPharma Inc

NASDAQ:ENTO

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 17 full-time employees. The company went IPO on 2016-10-11. The firm is focused on developing its pipeline of gut-restricted GI clinical product candidates, including niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, which is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The firm is advancing two separate clinical programs of niclosamide formulations, both of which are in Phase II clinical trials, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis. The adrulipase programs is focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.